¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"inhibition constant"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • rate constant
    ¼Óµµ»ó¼ö
  • radioactive constant
    ¹æ»ç´É»ó¼ö
  • spin-spin coupling constant
    ½ºÇɽºÇɰáÇÕ»ó¼ö
  • statistical constant
    Åë°è»ó¼ö
  • structural constant
    ±¸Á¶»ó¼ö
  • sedimentation constant
    ħ°­»ó¼ö
  • universal constant
    º¸Æí»ó¼ö
  • universal gravitation constant
    ¸¸À¯Àη»ó¼ö
  • velocity constant
    ¼Óµµ»ó¼ö
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • filtration constant
    ¿©°ú»ó¼ö
  • growth rate constant
    Áõ½Ä·ü»ó¼ö
  • ionization constant
    ÀÌ¿ÂÈ­»ó¼ö
  • kerma rate constant
    Ä¿¸¶À²»ó¼ö
  • mean corpuscular constant
    Æò±ÕÀûÇ÷±¸»ó¼ö
  • permeability constant
    Åõ°ú»ó¼ö
  • phase constant
    À§»ó»ó¼ö
  • polarization constant
    ºÐ±Ø»ó¼ö
  • quantum constant
    ¾çÀÚ»ó¼ö
  • radioactive constant
    ¹æ»ç´É»ó¼ö
  • rate constant
    ¼Óµµ»ó¼ö
  • sedimentation constant
    ħ°­»ó¼ö
  • spin spin coupling constant
    ½ºÇɽºÇɰáÇÕ»ó¼ö
  • statistical constant
    Åë°è»ó¼ö
  • structural constant
    ±¸Á¶»ó¼ö
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • presynaptic inhibition
    ½Å°æÁ¢ÇÕÀü ¾ïÁ¦
  • reciprocal inhibition
    »ó¹Ý¾ïÁ¦(ßÓÚãåäð¤).
  • reciprocal inhibition
    »óÈ£¾ïÁ¦
  • reciprocal inhibition psychotherapy
    »óÈ£Á¦ÁöÁ¤½ÅÄ¡·á.
  • recurrent inhibition
    ¹Ý·ù(¼º) ¾ïÁ¦(Úãêüàõ åäð¤).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • agglutination inhibition test
    ÀÀÁý¾ïÁ¦½ÃÇè(¡­åäð¤ãËúÐ).
  • allogen(a)ic inhibition
    µ¿Á¾¼¼Æ÷ÀúÁö(¡­á¬øàðæò­).
  • antidromic inhibition
    ¿ª¹æÇ⼺ ¾ïÁ¦ (¡­åäð¤)
  • cardiac inhibition
    ½ÉÀå ¾ïÁ¦(ãýíôåäð¤)
  • cell,contact inhibition
    Á¢Ã˾ïÁ¦ (ïÈõºåäð¤)
  • chemical inhibition isoagglutinin
    È­ÇÐÀû ¾ïÁ¦ µ¿Á¾ÀÀÁý¼Ò
  • colony inhibition
    ±ÕÁý¶ô¾ïÁ¦(жó¢Õªåäð¤), ±ºÃ¼¾ïÁ¦(ÏØô÷åäð¤).
  • colony inhibition test
    Áý¶ôÇü¼º ÀúÁö½ÃÇè, ¼¼Æ÷±ºÇü¼º ÀúÁö½ÃÇè
  • competitive antagonism/inhibition
    °æÀïÀû ±æÇ×/¾ïÁ¦.
  • competitive inhibition
    °æÀïÀû ¾ïÁ¦, °æÇÕ¼º ¾ïÁ¦(Ìæùêàõåäð¤).
  • competitive inhibition
    °æÇÕÀúÇØ(ÌæùêîÁúª).
  • competitive inhibition
    °æÀïÀû¾ïÁ¦
  • competitive inhibition
    °æÀïÀû¾ïÁ¦
  • complement fixation inhibition test
    º¸Ã¼°íÁ¤ÀúÇØ½ÃÇè(ÜÍô÷ͳïÒîÁúªãËúÐ).
  • complement fixation inhibition test
    º¸Ã¼°áÇÕÀúÇØ½ÃÇè(ÜÍô÷Ì¿ùêîÁúªãËúÐ).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • equilibrium constant
    ÆòÇü»ó¼ö(øÁû¬ßÈâ¦)
  • exponential growth rate constant
    Áö¼ö ¼ºÀå¼Óµµ »ó¼ö (ò¦â¦à÷íþáÜÓøßÈâ¦)
  • formation constant
    Çü¼º »ó¼ö(û¡à÷ßÈâ¦)
  • gas constant
    ±âü »ó¼ö (Ѩô÷ßÈâ¦)
  • growth rate constant
    ¼ºÀå¼Óµµ »ó¼ö (à÷íþáÜÓøßÈâ¦)
  • hydrolysis constant
    °¡¼öºÐÇØ(Ê¥â©ÝÂú°) »ó¼ö(ßÈâ¦)
  • hydrophobicity constant
    ¼Ò¼ö¼º »ó¼ö(áÂâ©àõßÈâ¦)
  • rate constant
    ¼Óµµ»ó¼ö(áÜÓøßÈâ¦)
  • inhibitor constant
    ÀúÇØÁ¦»ó¼ö(îÁúªð¥ßÈâ¦)
  • intrinsic association constant
    °íÀ¯ ¿¬ÇÕ»ó¼ö(ͳêóÖ¤ùêßÈâ¦)
  • intrinsic dissociation constant
    °íÀ¯ ÇØ¸®»ó¼ö(ͳêóú°×îßÈâ¦)
  • ionization constant
    ÀÌ¿ÂÈ­(ûù) »ó¼ö(ßÈâ¦)
  • kinetic constant
    ¹ÝÀÀ¼Óµµ»ó¼ö(ÚãëëáÜÓøßÈâ¦)
  • law of constant heat summation
    Á¾ÇÕ¿­ºÒº¯¹ýÄ¢(ðüùêæðÝÕܨÛööÎ)
  • macroscopic binding constant
    °Å½Ã °áÇÕ»ó¼ö(ËÝãÊÌ¿ùêßÈâ¦)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
CRA central retinal artery; Chinese restaurant asthma; chronic rheumatoid arthritis; constant relative a...
CS calf serum; campomelic syndrome; carcinoid syndrome; cardiogenic shock; caries-susceptible; carotid ...
Cv specific heat at constant volume
Cv constant volume
DSCF Doppler-shifted constant frequency
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
HI Haemagglutination Inhibition
HI Haemagglutination inhibition test
HIT Hemagglutination inhibition test
HLI Hemolysis inhibition
ITIM immunoreceptor tyrosine-based inhibition motif
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
proactive inhibition The state or process hypothesised to account for poorer learning rate for elements later in a series as compared to the learning rate for elements coming earlier in a series.
(12 Dec 1998)
product inhibition Inhibition of an enzyme activity by a product of the reaction catalyzed by that enzyme.
(05 Mar 2000)
selective inhibition <chemistry> Inhibitor that occupies the active site of an enzyme or the binding site of a receptor and prevents the normal substrate or ligand from binding.
at sufficiently high concentration of the normal ligand inhibition is lost: the Km is altered by the competitive inhibitor, but the Vmax remains the same.
(05 Jan 1998)
noncompetitive inhibition <chemistry> A form of enzyme inhibition which cannot be reversed by increasing the amount of substrate in the reaction.
(09 Oct 1997)
substrate inhibition Inhibition of an enzyme activity by a substrate of the reaction catalyzed by that enzyme; often, this type of inhibition occurs at elevated substrate levels in which the substrate is binding to a second, non-active site on the enzyme.
(05 Mar 2000)
nonreciprocal contact inhibition <cell biology> Collision behaviour between different cell types in which one cell shows contact inhibition of locomotion and the other does not. An example is the interaction between sarcoma cells and fibroblasts (the former not being inhibited).
(18 Nov 1997)
density dependent inhibition of growth <cell culture> The phenomenon exhibited by most normal (anchorage dependent) animal cells in culture that stop dividing once a critical cell density is reached.
The critical density is considerably higher for most cells than the density at which a monolayer is formed, for this reason, most cell behaviourists prefer the term density dependent inhibition of growth as this avoids any confusion with contact inhibition of locomotion, a totally different phenomenon that is contact dependent.
(12 Jan 1998)
inhibition 1. Arrest or restraint of a process.
2. <psychology> The interference with or prevention of a behavioural or verbal response even though the stimulus for that response is present; in psychoanalysis the unconscious restraining of an instinctual process.
Origin: L. Inhibere = to restrain, habere = to hold
(04 Jul 1999)
inhibition factor <growth factor> A soluble, nondialysable factor that is produced by sensitised lymphocytes following exposure to a specific antigen. It inhibits macrophage migration and causes adherence.
It was originally defined on the basis of inhibition of emigration of mononuclear cells from capillary (haematocrit) tubes, more recently a 13 kD protein with migration inhibitory activity has been isolated.
Acronym: MIF
Synonym: inhibition factor.
(22 Sep 2002)
tissue thromboplastin inhibition time A test used to identify lupus anticoagulant; the thromboplastin source used in the prothrombin test is diluted to increase sensitivity to inhibitors.
(05 Mar 2000)
end product inhibition <biochemistry, physiology> The process of the end product of a particular metabolic reaction inhibiting an allosteric enzyme involved in that reaction as the reaction starts again, thus breaking the reaction cycle.
(09 Oct 1997)
enzyme inhibition theory of narcosis That narcotics inhibit respiratory enzymes by suppression of the formation of high energy phosphate bonds within the cell.
(05 Mar 2000)
uncompetitive inhibition An inhibitory effect on a metabolic function, such as an enzyme, not based on competition for the binding site of the naturally occurring substrate, but on a different effect on the molecule whose function is being inhibited.
(05 Mar 2000)
feedback inhibition <biochemistry, physiology> The process of the end product of a particular metabolic reaction inhibiting an allosteric enzyme involved in that reaction as the reaction starts again, thus breaking the reaction cycle.
(09 Oct 1997)
zone of inhibition <microbiology> The area of no bacterial browth around an antimicrobial agent in the disk-diffusion test.
(09 Oct 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
ÅëÇÕ°Ë»ö ¿Ï·á